Free Trial
NASDAQ:IMA

Ikena Oncology Q1 2024 Earnings Report

Ikena Oncology logo
$17.28 -0.62 (-3.46%)
As of 08/1/2025 04:00 PM Eastern

Ikena Oncology EPS Results

Actual EPS
-$3.36
Consensus EPS
-$4.80
Beat/Miss
Beat by +$1.44
One Year Ago EPS
N/A

Ikena Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ikena Oncology Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Monday, May 13, 2024
Conference Call Time
2:00AM ET

Upcoming Earnings

Ikena Oncology's next earnings date is estimated for Thursday, August 14, 2025, based on past reporting schedules.

Ikena Oncology Earnings Headlines

Protect Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
See More Ikena Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ikena Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ikena Oncology and other key companies, straight to your email.

About Ikena Oncology

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology (NASDAQ:IMA) and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

View Ikena Oncology Profile

More Earnings Resources from MarketBeat